Figure 5.
Integrin α6 deletion in murine BCR-ABL1+ (p210) B-ALL cells affects Src signaling. (A) α6fl/fl BCR-ABL1+ (p210) x CreERT2 (Cre) and x EmptyERT2 (Emy) cells treated with tamoxifen (TAM) for 24 hours followed by western blot analysis using an anti-phosphotyrosine Ab (clone 4G10). One of 3 experiments is shown. (B) Phosphotyrosine proteomics analysis was performed on murine cells treated for 16 hours or 3 days with tamoxifen. The fold changes (FCs) in the selected phosphotyrosine proteins were plotted. One experiment is shown.

Integrin α6 deletion in murine BCR-ABL1+ (p210) B-ALL cells affects Src signaling. (A) α6fl/fl BCR-ABL1+ (p210) x CreERT2 (Cre) and x EmptyERT2 (Emy) cells treated with tamoxifen (TAM) for 24 hours followed by western blot analysis using an anti-phosphotyrosine Ab (clone 4G10). One of 3 experiments is shown. (B) Phosphotyrosine proteomics analysis was performed on murine cells treated for 16 hours or 3 days with tamoxifen. The fold changes (FCs) in the selected phosphotyrosine proteins were plotted. One experiment is shown.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal